No ka pale ʻana i ka maʻi maʻi type 1, pono e pale ʻia nā cell i loko o ka pancreas no ka hana ʻana i ka insulin i nā poʻe i pilikia nui i ka maʻi. Wahi a ka Canadian Diabetes Association, ʻaʻohe ʻaʻohe ala kūpono a palekana i kēia manawa e pale aku i keia mai, ʻoiai inā mākou e kamaʻilio mua loa i ke ola o kahi keiki i manaʻo ʻia he pilikia. No laila, pono e hana ʻia nā ʻanuʻu e pale aku ai i ka maʻi maʻi type 1 me ka launa pū ʻana me ke kauka a i kekahi mau hihia, ma ke ʻano o kahi noiʻi hoʻokolohua.⁴.

Ke hoʻomau nei i ka noiʻi

• ʻĀpana D. Ua hōʻike ʻia kekahi mau noiʻi nānā ʻana ʻo ka hoʻohui ʻana i ka vitamina D o nā keiki liʻiliʻi i hoʻohaʻahaʻa loa i ka pilikia o ka hoʻomohala ʻana i ka maʻi maʻi type 1 (mai ka 400 IU a hiki i ka 2 IU o kēlā me kēia lā)¹³. Eia naʻe, ʻaʻohe hoʻokolohua lapaʻau i hiki mai e hōʻoia i kēia.¹¹. Ma muli o ka loaʻa ʻole o nā pilikia e pili ana i ka lawe ʻana i ka huaora D a me kāna mau pono olakino he nui, ʻōlelo kekahi mau kauka ma ke ʻano he mea pale;
• immunotherapy. ʻO kēia ke ala maikaʻi loa, a ʻo ia ka mea e hoʻopukapuka nui ai nā ʻepekema. ʻO ka Immunotherapy ka manaʻo e ʻae i ka ʻōnaehana pale e "ʻae" i nā cell i loko o ka pancreas kuleana no ka hana ʻana i ka insulin. Ke hoʻāʻo ʻia nei kekahi mau ʻano immunotherapy, no ka laʻana⁵ : he kano i hakuia me na antigens mai ka pancreas o ke kanaka e lapaau ia; kahi hoʻololi autologous o nā pūnaewele immune e wehe i nā pūnaewele luku a ʻae i ka hoʻomohala ʻana o nā cell tolerant hou; a me ke kahe o ke koko i laweia mai ka umbilical cord i ka manawa o ka hanau ana (i na keiki liilii);
• ʻO Vitamin B3. Nā lā ma ka vitro a ua kākoʻo nā hoʻāʻo holoholona i ke kuhiakau e loaʻa paha i ka niacinamide (vitamina B3) ka hopena pale i nā cell beta pancreatic. Ua hānai pū kekahi mau hoʻokolohua lapaʻau mua i kēia manaʻolana⁶. Akā naʻe, ʻaʻole i loaʻa i nā noiʻi nui nā hopena hōʻoia. No ka laʻana, ma ke ʻano he ʻāpana o ka European Nicotinamide Diabetes Intervention Trial (ENDIT)⁷, ua hāʻawi ʻia nā mea kiʻekiʻe o ka niacinamide a i ʻole kahi placebo i ka poʻe 552 i ka pilikia o ka maʻi maʻi type 1 (pili i ka pili pili, ka loaʻa ʻana o nā autoantibodies kūʻē i ka pancreas a me ka hoʻāʻo ʻana o ka glucose tolerance maʻamau). ʻAʻole i hōʻemi ʻo Niacinamide i ka hoʻomohala ʻana i ka maʻi diabetes.
• ʻO ka hoʻokomo ʻana i ka insulin haʻahaʻa. ʻO kekahi o nā ala pale i hoʻāʻo ʻia ʻo ia ka hāʻawi ʻana i nā ʻāpana liʻiliʻi o ka insulin i ka poʻe i pilikia. Ua loiloi ʻia kēia ala ma ke ʻano he ʻāpana o ka Diabetes Prevention Trial - Type 1^8,9. ʻAʻole i loaʻa i ka lāʻau insulin ka hopena pale koe wale nō i loko o kahi pūʻulu kiʻekiʻe o ka pilikia, kahi i lohi iki ai ka hoʻomaka ʻana o ka maʻi diabetes.

ʻO kekahi o nā paʻakikī o ka noiʻi ʻana ʻo ia ka hoʻopaʻa ʻana i ka poʻe i pilikia loa i ka hoʻomohala ʻana i ka maʻi. ʻO ke ʻano o ke koko o nā antibodies e kūʻē i nā cell beta o ka pancreas (autoantibodies) kekahi o nā hōʻailona i aʻo ʻia. Hiki ke loaʻa kēia mau antibodies i nā makahiki ma mua o ka hoʻomaka ʻana o ka maʻi. No ka mea he nui nā ʻano o kēia mau antibodies, he nīnau ia no ka ʻike ʻana i nā mea ʻoi loa ka wānana o ka maʻi, a mai ka nui o ka nui.¹⁰.

E noʻonoʻo i kā mākou pepa Complications of Diabetes.